NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

about

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

Item

http://www.wikidata.org/entity/Q49695446

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@en

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@nl

type

Item

label

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@en

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@nl

prefLabel

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@en

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@nl

P1476

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.

@en

P2093

Chisato Kameoka

http://www.w3.org/2001/XMLSchema#string

Ikumi Nakajo

http://www.w3.org/2001/XMLSchema#string

Ronald A Smulders

http://www.w3.org/2001/XMLSchema#string

Satoshi Yoshida

http://www.w3.org/2001/XMLSchema#string

Tadao Akizawa

http://www.w3.org/2001/XMLSchema#string

Tobias E Larsson

http://www.w3.org/2001/XMLSchema#string

Yuta Taniuchi

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis

Hyperphosphatemia Management in Patients with Chronic Kidney Disease

Oral phosphate binders in patients with kidney failure

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.

Intestinal npt2b plays a major role in phosphate absorption and homeostasis.

Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.

Intestinal phosphate transport.

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis

P304

73-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EKIR.2017.08.003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29340316

http://www.w3.org/2001/XMLSchema#string

P932

5762974

http://www.w3.org/2001/XMLSchema#string